Voyager Therapeutics financials
$2.64−2.22%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $40.4M | $80.0M | $250.0M | $40.9M | $37.4M | $171.1M | $104.4M | $7.6M | $10.1M | $14.2M |
| Gross profit | $40.4M | $80.0M | $250.0M | $40.9M | $37.4M | $171.1M | $104.4M | $7.6M | $10.1M | $14.2M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$131.8M | -$83.3M | $122.0M | -$50.8M | -$73.6M | $27.4M | -$51.7M | -$91.1M | -$71.9M | -$41.3M |
| Net income | -$119.7M | -$65.0M | $132.3M | -$46.4M | -$71.2M | $36.7M | -$43.6M | -$88.3M | -$70.7M | -$40.2M |
| Net margin | −296.5% | −81.3% | 52.9% | −113.4% | −190.3% | 21.5% | −41.8% | −1158.8% | −697.6% | −282.7% |
| Diluted EPS | $-2.04 | $-1.13 | $2.97 | $-1.21 | $-1.89 | $0.98 | $-1.21 | $-2.75 | $-2.64 | $-1.59 |
| EBITDA | -$127.8M | -$78.6M | $126.5M | -$44.6M | -$68.5M | $31.2M | -$48.9M | -$89.0M | -$70.3M | -$40.7M |
| Operating cash flow | -$132.5M | -$15.3M | $77.9M | -$12.5M | -$53.5M | -$96.7M | $48.7M | -$15.9M | -$61.4M | -$42.5M |
| Free cash flow | -$135.1M | -$18.8M | $74.7M | -$15.0M | -$55.1M | -$108.8M | $40.9M | -$20.2M | -$65.3M | -$47.5M |
| Diluted shares | 58.7M | 57.7M | 44.6M | 38.4M | 37.7M | 37.3M | 35.9M | 32.1M | 26.8M | 25.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $65.3M | $71.4M | $68.8M | $99.0M | $117.4M | $104.4M |
| Short-term investments | $131.1M | $195.3M | $162.1M | $19.9M | $15.1M | $76.7M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $252.3M | $393.1M | $351.3M | $159.4M | $193.9M | $261.6M |
| Total liabilities | $56.2M | $93.3M | $115.0M | $100.3M | $98.8M | $107.3M |
| Shareholders' equity | $196.1M | $299.8M | $236.3M | $59.0M | $95.1M | $154.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology